NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Acute Suicidal Ideation and Behavior: The SBD-ASIB Study
Not yet recruiting
Phase of Trial: Phase II/III
Latest Information Update: 21 Mar 2018
At a glance
- Drugs Cycloserine/lurasidone (Primary) ; Ketamine; Lurasidone
- Indications Bipolar depression; Suicidal ideation
- Focus Therapeutic Use
- Acronyms SBD-ASIB
- Sponsors NeuroRX
- 16 Mar 2018 Planned number of patients changed from 155 to 72.
- 16 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 1 May 2018.
- 12 Jan 2018 New trial record